Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study

Background: Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban. Methods: With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15–50 mL/min, weight ≤60 kg, and/or use of strong p-glycoprotein inhibitors) of patients from... Mehr ...

Verfasser: de Vries, Tim T.A.C.
Hemels, Martin M.E.W.
Cools, Frank
Crijns, Harry JGM H.J.G.M.
Yperzeele, Laetitia
Vanacker, Peter
Blankoff, Ivan
Lancellotti, Patrizio
Mairesse, Georges G.H.
de Veer, Anne
Casado Arroyo, Ruben
Catez, Emmanuel
De Pauw, Marleen
Vanassche, Thomas
de Asmundis, Carlo
Kirchhof, Paulus
De Caterina, Raffaele
de Groot, Joris J.R.
Dokumenttyp: Artikel
Erscheinungsdatum: 2020
Schlagwörter: Cardiologie et circulation / Aged / Anticoagulants / Atrial Fibrillation -- complications -- drug therapy -- epidemiology / Belgium -- epidemiology / Europe -- epidemiology / Factor Xa Inhibitors -- therapeutic use / Humans / Netherlands -- epidemiology / Prospective Studies / Pyridines -- therapeutic use / Thiazoles -- therapeutic use / Treatment Outcome / clinical trial / phase IV / haemorrhage / off-label use / stroke / thromboembolism
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29373258
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/319130